GIST

Deciphera Announces Positive CHMP Opinion for QINLOCK® for the Treatment of Fourth-line Gastrointestinal Stromal Tumor

Friday, September 17, 2021 - 1:17pm

Deciphera Press Release: FDA Grants Full Approval of Deciphera Pharmaceuticals QINLOCK (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor [online] May 15, 2020.

Key Points: 
  • Deciphera Press Release: FDA Grants Full Approval of Deciphera Pharmaceuticals QINLOCK (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor [online] May 15, 2020.
  • Deciphera Press Release: Deciphera Announces Australian Therapeutic Goods Administrations Approval of QINLOCK (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor [online] July 14, 2020.
  • Deciphera Press Release: Deciphera Announces Health Canadas Authorization of QINLOCK (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor [online] June 22, 2020.
  • Zai Lab Press Release: QINLOCK (Ripretinib) Approved in Taiwan for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST) [online] September 1, 2021.

Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European Society for Medical Oncology (ESMO) Congress 2021

Friday, September 17, 2021 - 12:00pm

We are equally encouraged by the tolerability and efficacy data presented today from the Phase 1/2 study of vimseltinib in TGCT.

Key Points: 
  • We are equally encouraged by the tolerability and efficacy data presented today from the Phase 1/2 study of vimseltinib in TGCT.
  • The data presented today with vimseltinib in TGCT reinforce its potential to be a best-in-class treatment for this disease.
  • The data presented today is from the second stage of Part 2 of the Simon two-stage design in PROC.
  • QINLOCK and the QINLOCK logo are registered trademarks, and Deciphera and the Deciphera logo are trademarks, of Deciphera Pharmaceuticals, LLC.

Edison Investment Research Limited: Immunicum (IMMU): Primed for value appreciation

Wednesday, September 15, 2021 - 9:06am

Given the changes to the R&D pipeline and updated strategy, we have revised our forecasts and valuation and present a new investment thesis.

Key Points: 
  • Given the changes to the R&D pipeline and updated strategy, we have revised our forecasts and valuation and present a new investment thesis.
  • We value Immunicum at SEK1.95bn or SEK9.76 per share (rNPV using a 12.5% discount rate and SEK212m cash at end-Q221).
  • About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors.
  • Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector.

Under the Scanner: Gwangju Institute of Science and Technology Scientists Unravel the Inner Workings of DNA Repair Enzymes

Tuesday, September 14, 2021 - 4:46pm

Unravelling the DNA repair mechanism opens possibilities for cancer detection and targeted gene repair.

Key Points: 
  • Unravelling the DNA repair mechanism opens possibilities for cancer detection and targeted gene repair.
  • In such a scenario, a set of enzymes (proteins that act as catalysts for biochemical reactions) are activated to repair the damage.
  • The sequence of processes undertaken by the enzymes to fix DNA damage is known as "base excision repair" (BER).
  • "This study provides insights for investigation of operational mechanisms of other enzymes involved in DNA repair.

Deciphera Pharmaceuticals to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss Rebastinib and Vimseltinib Data Presented at ESMO Congress 2021

Friday, September 10, 2021 - 12:00pm

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that the Company will host a virtual investor event to review the rebastinib and vimseltinib clinical data to be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2021 on Friday, September 17, 2021, from 10:00 AM to 12:30 PM ET.

Key Points: 
  • Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that the Company will host a virtual investor event to review the rebastinib and vimseltinib clinical data to be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2021 on Friday, September 17, 2021, from 10:00 AM to 12:30 PM ET.
  • Decipheras senior executive team will be joined by the following key opinion leaders at the event:
    A live webcast of the event may be accessed through the Investors section of Decipheras website at www.deciphera.com .
  • A replay of the webcast will be available following the event.
  • Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer.

Deciphera Pharmaceuticals, Inc. to Present at the 19th Annual Morgan Stanley Global Healthcare Conference

Thursday, September 2, 2021 - 12:00pm

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference on September 9, 2021 at 2:45 PM ET.

Key Points: 
  • Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference on September 9, 2021 at 2:45 PM ET.
  • A live webcast of the event will be available on the Events and Presentations page in the Investors section of the Companys website at https://investors.deciphera.com/events-presentations .
  • A replay of the webcast will be archived on the Companys website for 90 days following the presentation.
  • Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer.

NeoImmuneTech Appoints Jean Fan, M.D., as Chief Clinical Officer

Wednesday, August 25, 2021 - 12:00pm

NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced the appointment of Jean Fan, M.D., as Chief Clinical Officer (CCO).

Key Points: 
  • NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced the appointment of Jean Fan, M.D., as Chief Clinical Officer (CCO).
  • Fan brings over 20 years of experience in oncology and hematology leadership and clinical development to this role.
  • Fans contributions to our Clinical Development team thus far, and I am pleased to welcome her to the newly created role of Chief Clinical Officer, said Se Hwan Yang, Ph.D., President and Chief Executive Officer of NeoImmuneTech (NIT).
  • Fan joined NIT in 2020 as VP, Head of Clinical Development, coming from Blueprint Medicines where she served as VP, Clinical Development.

The Gwangju Institute of Science and Technology Study Examines Thin Film Surface Symmetries

Friday, August 13, 2021 - 1:36pm

Now, with the advent of nanotechnology and recent progress in thin film manufacturing, surface and interface properties offer a vast playground to engineer unprecedented functionalities and conduct physics research.

Key Points: 
  • Now, with the advent of nanotechnology and recent progress in thin film manufacturing, surface and interface properties offer a vast playground to engineer unprecedented functionalities and conduct physics research.
  • In a recent study published in Applied Surface Science , a team of scientists led by Associate Professor Jong Seok Lee from the Gwangju Institute of Science and Technology (GIST) in Korea reported a promising all-optical approach to analyze crystal structures in the bulk, interface, and surface of materials.
  • This study was carried out in collaboration with Seoul National University and the Institute for Basic Science, which are both in Korea.
  • Let us hope this work makes the surface of materials less difficult to investigate and easier to exploit!